Posts by: Alberto Molano

News

Roche Canada is contributing $2.125 million to the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo), a partnership initiative with the Multiple Sclerosis Society of Canada, the ... Read more

March 29, 2019March 29, 2019

$1.5M Earmarked for MS Research on Cannabis in Canada

News

In partnership with the Canadian Institutes of Health Research, the MS Society of Canada has announced $1.5 million to fund research over five years on the effects of cannabis on multiple sclerosis ... Read more

March 11, 2019March 11, 2019

Immunic Therapeutics Enrolls First Patient in Phase 2 Trial of IMU-838 for RRMS

Aubagio, News

Immunic Therapeutics has enrolled the first patient in its Phase 2 clinical trial testing IMU-838, a potential oral therapy for relapsing-remitting multiple sclerosis (RRMS). IMU-838 (vidofludimus calcium) is a next-generation selective ... Read more

February 25, 2019February 28, 2019

Study Indicates Possible Correlation Between Nutritional Status, MS

News

Multiple sclerosis (MS) patients eat a more limited diet, with a lower average of 31 nutrients, including zinc, thiamin, and iron, when compared with healthy controls, a study shows. ... Read more

January 22, 2019January 22, 2019

Controlling Spasticity Would Greatly Improve Everyday Quality of Life, Survey Shows

News

An international survey of caregivers and adults with neurological diseases, including multiple sclerosis (MS), revealed that spasticity is a hidden burden, having a negative effect on the ability to ... Read more

January 4, 2019January 10, 2019

Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS

News

Banner Life Sciences has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogen’s ... Read more

December 21, 2018January 3, 2019

Study Links Food Allergies and Increased MS Disease Activity

News

Multiple sclerosis (MS) patients who reported food allergies showed a 27 percent higher cumulative rate of flare-ups over the course of their disease, and more than twice the likelihood ... Read more

December 19, 2018December 19, 2018

FDA Gives Green Light to Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Patients

News

The U.S. Food and Drug Administration (FDA) has approved BrainStorm Cell Therapeutics‘ request to open a Phase 2 clinical trial testing the safety and effectiveness of its proprietary NurOwn mesenchymal ... Read more

December 7, 2018December 7, 2018

Tysabri Seen as Superior to IFN-β in Preventing Relapses, Easing Disability in Small Study

News

Tysabri (natalizumab) was found to be superior to interferon beta (IFN-β) in a small, 12-month study with relapsing-remitting multiple sclerosis (RRMS) patients, significantly decreasing their disability levels, its researchers ... Read more

November 30, 2018December 5, 2018

CDC Launching National Neurological Conditions Surveillance System to Study MS

News

The U.S. Congress is supporting with $5 million the National Neurological Conditions Surveillance System (NNCSS), an initiative to be launched by the Centers for Disease Control and Prevention (CDC) ... Read more

November 13, 2018November 13, 2018

Heavy Caseloads for MS Specialist Nurses in UK Compromise Patient Care, MS Trust Reports

News

Nurses who specialize in treating multiple sclerosis (MS) patients in the U.K. are handling heavier caseloads than recommended or preferred, resulting in patients going without the necessary care and support ... Read more

November 9, 2018November 9, 2018

Study Highlights Need for Better Engagement Between MS Patients and Healthcare Providers

News

Multiple sclerosis (MS) relapses can be challenging for some patients, and better engagement is needed between patients and their healthcare providers, a study focused on patient experiences has found. ... Read more

Posts by: Alberto Molano

Alberto Molano

In-Depth Study into MS Progression Gets $2M Boost from Roche Canada

$1.5M Earmarked for MS Research on Cannabis in Canada

Immunic Therapeutics Enrolls First Patient in Phase 2 Trial of IMU-838 for RRMS

Study Indicates Possible Correlation Between Nutritional Status, MS

Controlling Spasticity Would Greatly Improve Everyday Quality of Life, Survey Shows

Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS

Study Links Food Allergies and Increased MS Disease Activity

FDA Gives Green Light to Phase 2 Trial of NurOwn Stem Cell Therapy in Progressive MS Patients

Tysabri Seen as Superior to IFN-β in Preventing Relapses, Easing Disability in Small Study

CDC Launching National Neurological Conditions Surveillance System to Study MS

Heavy Caseloads for MS Specialist Nurses in UK Compromise Patient Care, MS Trust Reports

Study Highlights Need for Better Engagement Between MS Patients and Healthcare Providers

Pin It on Pinterest